MetaStat

MetaStat EBITDA Growth YoY

The Year-over-Year EBITDA Growth of MetaStat (MTST) as of Oct 11, 2026 is -3.39 %. In the previous year, Year-over-Year EBITDA Growth was 29.94 % — a change of -111.32% (lower).

EBITDA Growth YoY

-3.39 %

YoY

-111.32%

Last updated:

Year-over-Year EBITDA Growth of MetaStat is 2018 -3.39 % . Year-over-Year EBITDA Growth of MetaStat was 2017 29.94 % . It decreases by -111.32% lower compared to the previous year.

The MetaStat EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2015
-10.11 USD
Jan 1, 2016
0.25 USD
Jan 1, 2017
29.94 USD
Jan 1, 2018
-3.39 USD
The MetaStat EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-3.39 %-111.32%
29.94 %+11,756.39%
0.25 %-102.50%
-10.11 %—
Access this data via the Eulerpool API
Get Free API Key

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

Year-over-Year EBITDA Growth of MetaStat is -3.39 % in 2018.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth MetaStat since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's MetaStat historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Growth — MetaStat

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — MetaStat